AAPL   318.26 (+0.00%)
FB   226.04 (+0.26%)
GOOGL   1,423.51 (+0.37%)
AMZN   2,419.39 (+0.76%)
NVDA   342.62 (+0.92%)
CGC   17.86 (-17.77%)
BABA   199.59 (+0.05%)
MU   46.72 (+0.54%)
GE   6.65 (-2.06%)
TSLA   807.16 (+0.17%)
AMD   52.02 (+0.54%)
ACB   14.27 (-6.98%)
GILD   75.27 (-0.07%)
DIS   116.37 (-0.33%)
BA   145.97 (-2.57%)
AAPL   318.26 (+0.00%)
FB   226.04 (+0.26%)
GOOGL   1,423.51 (+0.37%)
AMZN   2,419.39 (+0.76%)
NVDA   342.62 (+0.92%)
CGC   17.86 (-17.77%)
BABA   199.59 (+0.05%)
MU   46.72 (+0.54%)
GE   6.65 (-2.06%)
TSLA   807.16 (+0.17%)
AMD   52.02 (+0.54%)
ACB   14.27 (-6.98%)
GILD   75.27 (-0.07%)
DIS   116.37 (-0.33%)
BA   145.97 (-2.57%)
AAPL   318.26 (+0.00%)
FB   226.04 (+0.26%)
GOOGL   1,423.51 (+0.37%)
AMZN   2,419.39 (+0.76%)
NVDA   342.62 (+0.92%)
CGC   17.86 (-17.77%)
BABA   199.59 (+0.05%)
MU   46.72 (+0.54%)
GE   6.65 (-2.06%)
TSLA   807.16 (+0.17%)
AMD   52.02 (+0.54%)
ACB   14.27 (-6.98%)
GILD   75.27 (-0.07%)
DIS   116.37 (-0.33%)
BA   145.97 (-2.57%)
AAPL   318.26 (+0.00%)
FB   226.04 (+0.26%)
GOOGL   1,423.51 (+0.37%)
AMZN   2,419.39 (+0.76%)
NVDA   342.62 (+0.92%)
CGC   17.86 (-17.77%)
BABA   199.59 (+0.05%)
MU   46.72 (+0.54%)
GE   6.65 (-2.06%)
TSLA   807.16 (+0.17%)
AMD   52.02 (+0.54%)
ACB   14.27 (-6.98%)
GILD   75.27 (-0.07%)
DIS   116.37 (-0.33%)
BA   145.97 (-2.57%)
Log in

NYSE:ZTSZoetis Stock Price, Forecast & News

$138.11
+2.47 (+1.82 %)
(As of 05/29/2020 08:58 AM ET)
Add
Compare
Today's Range
$137.46
Now: $138.11
$140.24
50-Day Range
$122.95
MA: $127.63
$135.64
52-Week Range
$90.14
Now: $138.11
$146.26
Volume2.35 million shs
Average Volume2.20 million shs
Market Capitalization$65.59 billion
P/E Ratio41.23
Dividend Yield0.59%
Beta0.78
Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites that include fleas, ticks, and worms. It also provides medicated feed additives that offer medicines to livestock; and other pharmaceutical products, which comprise allergy and dermatology, pain and sedation, antiemetic, reproductive, and oncology products. In addition, the company offers portable blood and urine analysis systems, and point-of-care diagnostic products, including instruments and reagents, rapid immunoassay tests, reference laboratory kits, and blood glucose monitors; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in complementary areas, such as biodevices and genetics. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.
Read More
Zoetis logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.3Community Rank: 3.2Dividend Strength: 4.2Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.39 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
CUSIP98978V10
Phone973-822-7000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$6.26 billion
Cash Flow$4.63 per share
Book Value$5.80 per share

Profitability

Net Income$1.50 billion

Miscellaneous

Employees10,600
Market Cap$65.59 billion
Next Earnings Date8/4/2020 (Estimated)
OptionableOptionable

Receive ZTS News and Ratings via Email

Sign-up to receive the latest news and ratings for ZTS and its competitors with MarketBeat's FREE daily newsletter.

Zoetis (NYSE:ZTS) Frequently Asked Questions

How has Zoetis' stock been impacted by COVID-19 (Coronavirus)?

Zoetis' stock was trading at $130.27 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ZTS shares have increased by 6.0% and is now trading at $138.11. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Zoetis?

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zoetis in the last year. There are currently 6 hold ratings, 9 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Zoetis.

When is Zoetis' next earnings date?

Zoetis is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Zoetis.

How were Zoetis' earnings last quarter?

Zoetis Inc (NYSE:ZTS) announced its earnings results on Wednesday, May, 6th. The company reported $0.95 EPS for the quarter, topping the Zacks' consensus estimate of $0.86 by $0.09. The company earned $1.53 billion during the quarter, compared to analysts' expectations of $1.50 billion. Zoetis had a net margin of 25.41% and a return on equity of 67.72%. The firm's revenue for the quarter was up 5.4% compared to the same quarter last year. During the same period in the previous year, the company earned $0.88 EPS. View Zoetis' earnings history.

How often does Zoetis pay dividends? What is the dividend yield for Zoetis?

Zoetis declared a quarterly dividend on Wednesday, May 20th. Stockholders of record on Friday, July 17th will be given a dividend of $0.20 per share on Tuesday, September 1st. This represents a $0.80 annualized dividend and a dividend yield of 0.58%. The ex-dividend date of this dividend is Thursday, July 16th. View Zoetis' dividend history.

How will Zoetis' stock buyback program work?

Zoetis announced that its board has approved a stock repurchase plan on Wednesday, December 12th 2018, which permits the company to repurchase $2,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization permits the company to buy up to 4.7% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company's management believes its stock is undervalued.

What guidance has Zoetis issued on next quarter's earnings?

Zoetis issued an update on its FY20 earnings guidance on Wednesday, May, 6th. The company provided earnings per share (EPS) guidance of $3.17-3.42 for the period, compared to the Thomson Reuters consensus EPS estimate of $3.66. The company issued revenue guidance of $5.95-6.25 billion, compared to the consensus revenue estimate of $6.44 billion.

What price target have analysts set for ZTS?

16 analysts have issued 1-year target prices for Zoetis' stock. Their forecasts range from $125.00 to $162.00. On average, they expect Zoetis' stock price to reach $141.50 in the next twelve months. This suggests a possible upside of 2.5% from the stock's current price. View analysts' price targets for Zoetis.

Has Zoetis been receiving favorable news coverage?

News headlines about ZTS stock have been trending somewhat positive recently, InfoTrie Sentiment reports. The research firm rates the sentiment of news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Zoetis earned a media sentiment score of 0.7 on InfoTrie's scale. They also gave media stories about the company a news buzz of 2.0 out of 10, meaning that recent news coverage is very unlikely to have an effect on the company's share price in the immediate future. View the latest news aboutZoetis.

Are investors shorting Zoetis?

Zoetis saw a decrease in short interest during the month of May. As of May 15th, there was short interest totaling 4,370,000 shares, a decrease of 5.2% from the April 30th total of 4,610,000 shares. Based on an average trading volume of 2,940,000 shares, the short-interest ratio is presently 1.5 days. Approximately 0.9% of the company's shares are short sold. View Zoetis' Current Options Chain.

Who are some of Zoetis' key competitors?

What other stocks do shareholders of Zoetis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zoetis investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Hawkins (HWKN), Aegean Marine Petroleum Network (ANW), Athabasca Oil (ATH), Micron Technology (MU), Accenture (ACN) and Transocean (RIG).

Who are Zoetis' key executives?

Zoetis' management team includes the following people:
  • Mr. Juan Ramón Alaix, CEO & Director (Age 68)
  • Mr. Glenn C. David, Exec. VP & CFO (Age 47)
  • Dr. Catherine A. Knupp, Exec. VP and Pres of R&D (Age 58)
  • Mr. Clinton A. Lewis Jr., EVP and Grp Pres of Intl. Ops., Comm. Devp., Glbl Genetics, Aquatic Health & Human Medical Digs (Age 52)
  • Ms. Kristin C. Peck, Exec. VP and Group Pres of U.S. Operations, Bus. Devel. & Strategy (Age 48)

What is Zoetis' stock symbol?

Zoetis trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZTS."

Who are Zoetis' major shareholders?

Zoetis' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (8.70%), State Street Corp (4.23%), Alliancebernstein L.P. (2.99%), Morgan Stanley (2.09%), Polen Capital Management LLC (2.06%) and Capital World Investors (1.99%). Company insiders that own Zoetis stock include Andrew Fenton, Catherine A Knupp, Clinton A Jr Lewis, Glenn David, Heidi C Chen, Juan Ramon Alaix, Khosla Sanjay, Kristin C Peck, Roman Trawicki, Roxanne Lagano and Willie M Reed. View institutional ownership trends for Zoetis.

Which major investors are selling Zoetis stock?

ZTS stock was sold by a variety of institutional investors in the last quarter, including 1832 Asset Management L.P., Massachusetts Financial Services Co. MA, Morgan Stanley, Polen Capital Management LLC, Wells Fargo & Company MN, Nuveen Asset Management LLC, Waddell & Reed Financial Inc., and Canada Pension Plan Investment Board. Company insiders that have sold Zoetis company stock in the last year include Andrew Fenton, Catherine A Knupp, Clinton A Jr Lewis, Glenn David, Heidi C Chen, Juan Ramon Alaix, Kristin C Peck, Roman Trawicki, Roxanne Lagano, and Willie M Reed. View insider buying and selling activity for Zoetis.

Which major investors are buying Zoetis stock?

ZTS stock was bought by a variety of institutional investors in the last quarter, including Capital International Investors, Capital Research Global Investors, FDx Advisors Inc., The Manufacturers Life Insurance Company , Eagle Asset Management Inc., Johnson Investment Counsel Inc., 1832 Asset Management L.P., and Sands Capital Management LLC. View insider buying and selling activity for Zoetis.

How do I buy shares of Zoetis?

Shares of ZTS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Zoetis' stock price today?

One share of ZTS stock can currently be purchased for approximately $138.11.

How big of a company is Zoetis?

Zoetis has a market capitalization of $65.59 billion and generates $6.26 billion in revenue each year. The company earns $1.50 billion in net income (profit) each year or $3.64 on an earnings per share basis. Zoetis employs 10,600 workers across the globe.

What is Zoetis' official website?

The official website for Zoetis is www.zoetis.com.

How can I contact Zoetis?

Zoetis' mailing address is 10 Sylvan Way, Parsippany NJ, 07054. The company can be reached via phone at 973-822-7000 or via email at [email protected]

This page was last updated on 5/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.